FDA Archives - Page 212 of 220

1 minute read

Federal Circuit Rules In Favor Of Natera, Upholding Invalidation Of CareDx Patents

July 18, 1:42 PM

Natera, Inc. (NASDAQ:NTRA), a leader in personalized genetic testing and diagnostics, today announced that the Federal Circuit Court of Appeals affirmed the Delaware Federal District Court's September

CDNA

1 minute read

White House Adviser Fauci To Retire Before Biden Term Ends; Won’t Stay Past Jan 2025

By Benzinga Newsdesk

July 18, 12:44 PM

-Bloomberg

SPY

1 minute read

FDA
News

Neuronetics Receives FDA 510(k) Premarket Notification Clearance For The Neurostar TMS Therapy System For Mental Health

By Benzinga Newsdesk

July 18, 11:26 AM

accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K220127

STIM

1 minute read

FDA
News

European Medicines Agency Says Started Evaluating The Use Of Pfizer’s Comirnaty In Children Aged 6 Months To 4 Years

By Benzinga Newsdesk

July 18, 11:24 AM

-Reuters

PFE

1 minute read

AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022

By Vandana Singh

July 18, 11:05 AM

Genmab A/S (NASDAQ:GMAB) has announced that AbbVie Inc (NASDAQ:ABBV) will submit a conditional marketing authorization application with the European Medicines Agency…

ABBV

1 minute read

FDA
News

AstraZeneca Says Vaxzevria 73% Effective At Preventing Omicron-related Infections After Fourth Dose, According To Real World Evidence Study In Thailand

By Benzinga Newsdesk

July 18, 11:03 AM

-Reuters

AZN

1 minute read

Apyx Medical’s Renuvion Scores FDA Approval To Eliminate Sagging Neck

By Vandana Singh

July 18, 10:40 AM

The FDA has granted 510(k) clearance for Apyx Medical Corporation’s (NASDAQ:APYX) Renuvion for subcutaneous dermatological and aesthetic procedures to improve the appearance…

APYX

4 minute read

Polyrizon Signed An Agreement With Nurexone For Intranasal Administration Of Therapy For Spinal Cord Injuries. BZ NOTE: Medigus Owns 37.03% Of Polyrizon

By Benzinga Newsdesk

July 18, 8:07 AM

Medigus: Polyrizon Signed an Agreement with Nurexone for Intranasal Administration of Cutting - Edge Therapy for Spinal Cord Injuries Polyrizon will be entitled for up to $3.35 million in addition to future

MDGS

2 minute read

Eledon Pharmaceuticals Announces The First Patient Dosed In Phase 1b Trial Evaluating Tegoprubart In Kidney Transplantation

By Benzinga Newsdesk

July 18, 8:01 AM

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ:ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell

ELDN

1 minute read

Eton Pharmaceuticals Announces FDA Approval Of ZONISADE

By Benzinga Newsdesk

July 18, 7:11 AM

Eton Pharmaceuticals, Inc. (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has

ETON